Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Risk Factors of Metastatic Lymph Nodes in Papillary Thyroid Microcarcinoma. Comm...
Journal Information
Vol. 98. Issue 8.
Pages 497-498 (October 2020)
Vol. 98. Issue 8.
Pages 497-498 (October 2020)
Letter to the Editor
Full text access
Risk Factors of Metastatic Lymph Nodes in Papillary Thyroid Microcarcinoma. Comment on Patients Selection for the Study
Factores de riesgo de metástasis ganglionares en el microcarcinoma papilar de tiroides. Comentario sobre la selección de pacientes para el estudio
Visits
...
María del Carmen González-Sáncheza,b,c,
Corresponding author
crmngs@hotmail.com

Corresponding author.
, Guzmán Franch-Arcasa,b,c
a Unidad de Cirugía Endocrina, Servicio de Cirugía General y Aparato Digestivo, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
b Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain
c Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
Related content
Cir Esp. 2020;98:219-2510.1016/j.cireng.2020.03.012
José Ruiz Pardo, Antonio Ríos, José M. Rodríguez, Miriam Paredes, Víctor Soriano, María I. Oviedo, Antonio M. Hernández, Pascual Parrilla
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor:

We have read with interest the recent article by Dr. José Ruiz Pardo et al.1 This is a retrospective study in which the authors compared a group of patients with papillary thyroid microcarcinoma and metastatic cervical lymphadenopathies (group 2, n = 15), with another group of patients without metastatic lymphadenopathies (group 1, n = 146) in order to identify predictive factors for the presence of lymph node metastases. The interest lies in the controversy over whether to perform prophylactic dissection of the central lymph node compartment in papillary thyroid cancer. Methodologically, it has not been possible to design or conduct a randomized study that could provide definitive data on this topic.2 Current scientific guidelines would reserve their use for cases of higher risk: advanced tumors (T3 or higher; >4 cm), multicentricity, patients older than 50 or younger than 15 years of age, or presence of lateral cervical metastases.3,4 Despite this, many surgical groups systematically perform prophylactic dissection of the central compartment, showing that 30–35% of cases with microcarcinoma present cervical metastatic lymphadenopathy in the final histological study.5–7

In the study presented by the authors, it is interesting that, in the group of 146 patients without lymph node metastases, only 11 (7.5%) underwent central compartment dissection. Therefore, in the remaining 135 cases (more than half incidental findings after thyroidectomy or another cause [87 patients]), no type of cervical lymph node dissection (central or lateral cervical) was performed. The following question arises: how can these patients be considered to have “no lymph node metastases”, knowing that lymph node metastases would have been found in 30–35% of cases if a central lymph node compartment dissection had been performed? In short, the authors compared a group of patients in whom lymph node metastases were diagnosed by lymph node dissection with another group of patients in whom the majority (>90%) did not undergo any type of lymph node dissection, and in whom it is unknown how many of them actually metastasized or not. A proper analysis would have compared patients with lymph node dissection and lymphadenopathies with no metastasis (n = 11, instead of n = 146) with patients with lymph node dissection and lymphadenopathies with metastasis (n = 15).

References
[1]
J. Ruiz Pardo, A. Rios, J.M. Rodriguez, M. Paredes, V. Soriano, M.I. Oviedo, et al.
Risk factors of metastatic lymph nodes in papillary thyroid microcarcinoma.
[2]
T. Carling, S.E. Carty, M.M. Ciarleglio, D.S. Cooper, G.M. Doherty, L.T. Kim, et al.
American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma.
Thyroid, 22 (2012), pp. 237-244
[3]
J.J. Sancho, T.W. Lennard, I. Paunovic, F. Triponez, A. Sitges-Serra.
Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES).
Langenbecks Arch Surg, 399 (2014), pp. 155-163
[4]
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, et al.
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer.
Thyroid, 26 (2016), pp. 1-133
[5]
L.S. Liu, J. Liang, J.H. Li, X. Liu, L. Jiang, J.X. Long, et al.
The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis.
Eur Arch Otorhinolaryngol, 274 (2017), pp. 1327-1338
[6]
Y. Luo, Y. Zhao, K. Chen, J. Shen, J. Shi, S. Lu, et al.
Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma.
J Endocrinol Invest, 42 (2019), pp. 227-236
[7]
C. Zhang, B.J. Li, Z. Liu, L.L. Wang, W. Cheng.
Predicting the factors associated with central lymph node metastasis in clinical node-negative (cN0) papillary thyroid microcarcinoma.
Eur Arch Otorhinolaryngol, 277 (2020), pp. 1191-1198

Please cite this article as: González-Sánchez M, Franch-Arcas G. Factores de riesgo de metástasis ganglionares en el microcarcinoma papilar de tiroides. Comentario sobre la selección de pacientes para el estudio. Cir Esp. 2020;98:496–497.

Copyright © 2020. AEC
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos